EZH2 and small cell lung carcinoma: Interestingly, the 5′ untranslated region of EZH2 was associated with sensitivity to AURK inhibitors and a fibroblast growth factor receptor (FGFR) inhibitor, suggesting that these therapies may be effective against SCLC cases where EZH2-mediated silencing of SLFN11 mediates chemoresistance.